1. T. Vos u. a., „Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019“, The Lancet, Bd. 396, Nr. 10258, S. 1204–1222, Okt. 2020, doi: 10.1016/S0140-6736(20)30925-9.

2. A. R. Falsey, P. A. Hennessey, M. A. Formica, C. Cox, und E. E. Walsh, „Respiratory syncytial virus infection in elderly and high-risk adults“, N Engl J Med, Bd. 352, Nr. 17, S. 1749–1759, Apr. 2005, doi: 10.1056/NEJMoa043951.

3. A. K. Grech, C. T. Foo, E. Paul, A. K. Aung, und C. Yu, „Epidemiological trends of respiratory tract pathogens detected via mPCR in Australian adult patients before COVID-19“, BMC Infectious Diseases, Bd. 24, Nr. 1, S. 38, Jan. 2024, doi: 10.1186/s12879-023-08750-7.

4. D. Knipe u. a., Fields Virology, Volumes 1 and 2. Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2013.

5. Z. Shang, S. Tan, und D. Ma, „Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies“, Int. J. Biol. Sci., Bd. 17, Nr. 14, S. 4073–4091, 2021, doi: 10.7150/ijbs.64762.

6. C. F. Estofolete u. a., „Clinical Characterization of Respiratory Syncytial Virus Infection in Adults: A Neglected Disease?“, Viruses, Bd. 15, Nr. 9, S. 1848, Aug. 2023, doi: 10.3390/v15091848.

7. M. Savic, Y. Penders, T. Shi, A. Branche, und J.-Y. Pirçon, „Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis“, Influenza Other Respir Viruses, Bd. 17, Nr. 1, S. e13031, Jan. 2023, doi: 10.1111/irv.13031.

8. D. Surie u. a., „Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥ 60 Years — IVY Network, 20 U.S. States, February 2022–May 2023“, MMWR Morb. Mortal. Wkly. Rep., Bd. 72, Nr. 40, S. 1083–1088, Okt. 2023, doi: 10.15585/mmwr.mm7240a2.

9. Arexvy European Medicines Agency (EMA)“. Accessed 24 Sep 2024. [Online]. https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy

10. Abrysvo European Medicines Agency (EMA)“. Accessed 24 Sep 2024. [Online]. https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo

11. mResvia European Medicines Agency (EMA)“. Accessed24 Sep 2024. [Online]. https://www.ema.europa.eu/en/medicines/human/EPAR/mresvia

12. E. T. Mendes u. a., „An outbreak of respiratory syncytial virus infection in hematopoietic stem cell transplantation outpatients: good outcome without specific antiviral treatment“, Transpl Infect Dis, Bd. 15, Nr. 1, S. 42–48, Feb. 2013, doi: 10.1111/j.1399-3062.2012.00764.x.

13. J. N. Shah und R. F. Chemaly, „Management of RSV infections in adult recipients of hematopoietic stem cell transplantation“, Blood, Bd. 117, Nr. 10, S. 2755–2763, März 2011, doi: 10.1182/blood-2010-08-263400.

14. T. N. Small u. a., „Respiratory syncytial virus infection following hematopoietic stem cell transplantation“, Bone Marrow Transplant, Bd. 29, Nr. 4, S. 321–327, Feb. 2002, doi: 10.1038/sj.bmt.1703365.

15. S. G. Kelly u. a., „Respiratory syncytial virus outbreak on an adult stem cell transplant unit“, Am J Infect Control, Bd. 44, Nr. 9, S. 1022–1026, Sep. 2016, doi: 10.1016/j.ajic.2016.03.075.

16. A. J. McCarthy u. a., „The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation“, Bone Marrow Transplant, Bd. 24, Nr. 12, S. 1315–1322, Dez. 1999, doi: 10.1038/sj.bmt.1702078.

17. S. Einarsdottir u. a., „Respiratory syncytial virus and other vaccine-preventable infections in Multiple Myeloma. A population-based study on 8672 myeloma patients diagnosed 2008–2021 from the Swedish Myeloma Registry“, Haematologica, Juni 2024, doi: 10.3324/haematol.2024.285161.

18. F. Khawaja und R. F. Chemaly, „Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies“, Haematologica, Bd. 104, Nr. 7, S. 1322–1331, Juli 2019, doi: 10.3324/haematol.2018.215152.

19. Y.-C. Chuang, K.-P. Lin, L.-A. Wang, T.-K. Yeh, und P.-Y. Liu, „The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review“, IDR, Bd. Volume 16, S. 661–675, Jan. 2023, doi: 10.2147/IDR.S396434.

20. R. F. Chemaly u. a., „An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection“, J Infect Dis, Bd. 206, Nr. 9, S. 1367–1371, Nov. 2012, doi: 10.1093/infdis/jis516.

21. P. Ljungman u. a., „Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation“, Bone Marrow Transplant, Bd. 28, Nr. 5, S. 479–484, Sep. 2001, doi: 10.1038/sj.bmt.1703139.

22. M. Mikulska u. a., „Epidemiology of viral respiratory tract infections in an outpatient haematology facility“, Ann Hematol, Bd. 93, Nr. 4, S. 669–676, Apr. 2014, doi: 10.1007/s00277-013-1912-0.

23. R. Martino u. a., „Respiratory virus infections in adults with hematologic malignancies: a prospective study“, Clin Infect Dis, Bd. 36, Nr. 1, S. 1–8, Jan. 2003, doi: 10.1086/344899.

24. E. Whimbey u. a., „Community respiratory virus infections among hospitalized adult bone marrow transplant recipients“, Clin Infect Dis, Bd. 22, Nr. 5, S. 778–782, Mai 1996, doi: 10.1093/clinids/22.5.778.

25. R. F. Chemaly u. a., „Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center“, Medicine (Baltimore), Bd. 85, Nr. 5, S. 278–287, Sep. 2006, doi: 10.1097/01.md.0000232560.22098.4e.

26. E. J. Anaissie u. a., „The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management“, Blood, Bd. 103, Nr. 5, S. 1611–1617, März 2004, doi: 10.1182/blood-2003-05-1425.

27. Y. Li, X. Wang, E. K. Broberg, H. Campbell, H. Nair, und European RSV Surveillance Network, „Seasonality of respiratory syncytial virus and its association with meteorological factors in 13 European countries, week 40 2010 to week 39 2019“, Euro Surveill, Bd. 27, Nr. 16, S. 2100619, Apr. 2022, doi: 10.2807/1560-7917.ES.2022.27.16.2100619.

28. Y. J. Juhn u. a., „Incidence of Respiratory Syncytial Virus Infection in Older Adults Before and During the COVID-19 Pandemic“, JAMA Netw Open, Bd. 6, Nr. 1, S. e2250634, Jan. 2023, doi: 10.1001/jamanetworkopen.2022.50634.

29. E. Vakil u. a., „Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies“, Transpl Infect Dis, Bd. 20, Nr. 6, S. e12994, Dez. 2018, doi: 10.1111/tid.12994.

30. R. F. Chemaly, D. P. Shah, und M. J. Boeckh, „Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies“, Clin Infect Dis, Bd. 59 Suppl 5, Nr. Suppl 5, S. S344-351, Nov. 2014, doi: 10.1093/cid/ciu623.

31. „Epidemiologisches Bulletin 32/2024“,. Accessed 23 Aug 2024, [Online]. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2024/Ausgaben/32_24.pdf?__blob=publicationFile

32. „2023_RSV-Impfung_DGP.pdf“. Accessed 23 Aug 2024. [Online]. https://pneumologie.de/storage/app/media/uploaded-files/2023_RSV-Impfung_DGP.pdf

33. J. A. Nacov u. a., „2642. Multipathogen Antigen Test Kit (MAK-5)– Distribution and Frequency of Viral Respiratory Diseases in Germany among Volunteers in the VACCELERATE Registry“, Open Forum Infectious Diseases, Bd. 10, Nr. Supplement_2, S. ofad500.2254, Dez. 2023, doi: 10.1093/ofid/ofad500.2254.